Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. (2015). Journal of Analytical Oncology, 4(3),  94-101. https://doi.org/10.6000/1927-7229.2015.04.03.1